Ann Dermatol.  2017 Dec;29(6):761-767. 10.5021/ad.2017.29.6.761.

Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database

• Lee JY
• Kang S
• Park JS
• Jo SJ

• KMID: 2395185
• DOI: http://doi.org/10.5021/ad.2017.29.6.761

Abstract

BACKGROUND
Although psoriasis is universal in its occurrence worldwide, its prevalence varies by geographic location and race. A few hospital-based surveys have reported on the demographic characteristics in Korean patients with psoriasis. However, a nation-wide study on the prevalence of psoriasis in Korea remains uncompleted.
OBJECTIVE
The purpose of this study was to determine the prevalence of psoriasis in Korea and to describe the demographic and social characteristics of afflicted individuals.
METHODS
We identified patients with psoriasis using a relevant diagnostic code from the sixth revision of the Korean Standard Classification of Disease in the 2011~2015 claims database of the Health Insurance Review and Assessment Service of Korea. We estimated the annual prevalence of psoriasis and described the age and sex distribution of the patients, type and severity of psoriasis, comorbidities, type of health insurance, type of health-care institution and residence area. Patients with moderate-to-severe psoriasis were defined as those who had been treated with phototherapy, classical systemic agents, and/or biologic agents.
RESULTS
The standardized prevalence of psoriasis was 453 per 100,000 individuals of the database population in 2015. We found male preponderance with a 1.3:1 male-to-female ratio, and that the largest number of patients belonged to the age group of 50s. Of the patients diagnosed with psoriasis in 2015, 83.8% had plaque psoriasis and 22.6% had moderate-to-severe psoriasis.
CONCLUSION
The annual standardized prevalence of psoriasis in Korea was 453 per 100,000 of the population in 2015.

Keyword

Demography; National health programs; Prevalence; Psoriasis

MeSH Terms

Biological Factors
Classification
Comorbidity
Continental Population Groups
Demography
Epidemiologic Studies*
Humans
Insurance, Health
Korea*
Male
National Health Programs*
Phototherapy
Prevalence*
Psoriasis*
Sex Distribution
Sociological Factors
Biological Factors

Figure

• 

  Fig. 1 Risk for moderate-to-severe psoriasis by age group between 2011 and 2015 in Korea.

Reference

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001; 15:16–17.

2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005; 52:23–26.

3. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007; 25:535–546.

4. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005; 141:1537–1541.

5. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996; 135:533–537.

6. Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh). 1989; 142:5–8.

7. Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in denmark. Acta Derm Venereol. 2017; 97:808–812.

8. Barisić-Drusko V, Paljan D, Kansky A, Vujasinović S. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh). 1989; 146:178–179.

9. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89:262–266.

10. Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015; 5:e006450.

11. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984; 10:965–958.

12. Oh EH, Ro YS, Kim JE. Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study. J Dermatol. 2017; 44:621–629.

13. Na SJ, Jo SJ, Youn JI. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol. 2013; 40:731–735.

14. Nam SH, Kim CW, Kim SS, Kim KH, Lee KW, Kim KJ. Correlations between HLA-Cw*0602 and clinical picture in Korean psoriatic patients. Korean J Dermatol. 2001; 39:183–189.

15. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26:314–320.

16. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63:40–46.

17. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol. 1997; 24:230–234.

18. Japanese Society For Psoriasis Research. Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol. 2011; 38:1125–1129.

19. Ferrándiz C, Bordas X, García-Patos V, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001; 15:20–23.

20. Fan X, Yang S, Sun LD, Liang YH, Gao M, Zhang KY, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol. 2007; 87:335–340.

21. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002; 46:867–873.

22. Ashcroft DM, Li Wan, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000; 25:1–10.

23. Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol. 2012; 51:53–58.

24. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13:450–456.

25. Bernhard JD. Clinical differences in juvenile vs adult-onset psoriasis. Br J Dermatol. 1996; 135:501–502.

26. Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015; 29:955–963.

27. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012; 26:Suppl 2. 3–11.

28. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010; 31:1000–1006.

29. Choi WJ, Park EJ, Kwon IH, Kim KH, Kim KJ. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol. 2010; 22:300–306.